{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:55:40Z","timestamp":1793163340362,"version":"4.5.0"},"reference-count":100,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n                    In the treatment of cancer, understanding the disease status, or accurate staging, is extremely important, and various imaging techniques are used. Computed tomography (CT), magnetic resonance imaging, and scintigrams are commonly used for solid tumors, and advances in these technologies have improved the accuracy of diagnosis. In the clinical practice of prostate cancer, CT and bone scans have been considered especially important for detecting metastases. Nowadays, CT and bone scans are called conventional methods because positron emission tomography (PET), especially prostate-specific membrane antigen (PSMA)\/PET, is extremely sensitive in detecting metastases. Advances in functional imaging, such as PET, are advancing the diagnosis of cancer by allowing information to be added to the morphological diagnosis. Furthermore, PSMA is known to be upregulated depending on the malignancy of the prostate cancer grade and resistance to therapy. Therefore, it is often highly expressed in castration-resistant prostate cancer (CRPC) with poor prognosis, and its therapeutic application has been attempted for around two decades. PSMA theranostics refers to a type of cancer treatment that combines both diagnosis and therapy using a PSMA. The theranostic approach uses a radioactive substance attached to a molecule that targets PSMA protein on cancer cells. This molecule is injected into the patient\u2019s bloodstream and can be used for both imaging the cancer cells with a PET scan (PSMA PET imaging) and delivering radiation directly to the cancer cells (PSMA-targeted radioligand therapy), with the aim of minimizing damage to healthy tissue. Recently, in an international phase III trial, the impact of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 therapy was studied in patients with advanced PSMA-positive metastatic CRPC who had previously been treated with specific inhibitors and regimens. The trial revealed that\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 significantly extended both progression-free survival and overall survival compared to standard care alone. Although there was a higher incidence of grade 3 or above adverse events with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617, it did not negatively impact the patients\u2019 quality of life. PSMA theranostics is currently being studied and used primarily for the treatment of prostate cancer, but it has the potential to be applied to other types of cancers as well.\n                  <\/jats:p>","DOI":"10.1177\/17588359231182293","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T08:17:37Z","timestamp":1688372257000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["The current status of prostate cancer treatment and PSMA theranostics"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-7965","authenticated-orcid":false,"given":"Motohide","family":"Uemura","sequence":"first","affiliation":[{"name":"Department of Urology, Fukushima Medical University School of Medicine, 1, Hikarigaoka, Fukushima 960-1295, Japan"},{"name":"Department of Urology, Iwase General Hospital, Sukagawa, Fukushima, Japan"},{"name":"Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tanji","sequence":"additional","affiliation":[{"name":"Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yaginuma","sequence":"additional","affiliation":[{"name":"Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"bibr1-17588359231182293","unstructured":"Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare. Cancer Statistics, 2023."},{"key":"bibr2-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1296"},{"key":"bibr3-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"bibr4-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"bibr5-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"bibr6-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"bibr7-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"bibr8-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"bibr9-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"bibr10-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203877"},{"key":"bibr11-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0193"},{"key":"bibr12-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00278-7"},{"key":"bibr13-17588359231182293","first-page":"81","volume":"3","author":"Silver DA","year":"1997","journal-title":"Clin Cancer Res"},{"key":"bibr14-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.030"},{"key":"bibr15-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01264-X"},{"key":"bibr16-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.11.005"},{"key":"bibr17-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"bibr18-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.175"},{"key":"bibr19-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"bibr20-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.022"},{"key":"bibr21-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000040"},{"key":"bibr22-17588359231182293","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera M","year":"2020","journal-title":"Eur Urol"},{"key":"bibr23-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000531"},{"key":"bibr24-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.01.042"},{"key":"bibr25-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-014-1903-9"},{"key":"bibr26-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.020"},{"key":"bibr27-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22764"},{"key":"bibr28-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"bibr29-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"bibr30-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"bibr31-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2524-z"},{"key":"bibr32-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05025-0"},{"key":"bibr33-17588359231182293","unstructured":"https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCTs022220021."},{"key":"bibr34-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0096"},{"key":"bibr35-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09516-0"},{"key":"bibr36-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05245-y"},{"key":"bibr37-17588359231182293","unstructured":"https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000042995."},{"key":"bibr38-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-020-00101-0"},{"key":"bibr39-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01602-x"},{"key":"bibr40-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2192351"},{"key":"bibr41-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1814151"},{"key":"bibr42-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002367"},{"key":"bibr43-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002013"},{"key":"bibr44-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.262250"},{"key":"bibr45-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.036"},{"key":"bibr46-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.018"},{"key":"bibr47-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"bibr48-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"bibr49-17588359231182293","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05114746."},{"key":"bibr50-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"bibr51-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1089"},{"key":"bibr52-17588359231182293","unstructured":"ClinicalTrials.gov.\n                      177\n                      Lu-PSMA-I&T for metastatic castration-resistant prostate cancer, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05204927."},{"key":"bibr53-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"bibr54-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158550"},{"key":"bibr55-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002210"},{"key":"bibr56-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"bibr57-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4044"},{"key":"bibr58-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"bibr59-17588359231182293","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050722"},{"key":"bibr60-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01617-4"},{"key":"bibr61-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251017"},{"key":"bibr62-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04612-0"},{"key":"bibr63-17588359231182293","doi-asserted-by":"publisher","DOI":"10.4103\/ijnm.IJNM_130_20"},{"key":"bibr64-17588359231182293","first-page":"62","volume":"61","author":"Sathekge M","year":"2020","journal-title":"J NuclMed"},{"key":"bibr65-17588359231182293","doi-asserted-by":"publisher","DOI":"10.7150\/thno.48107"},{"key":"bibr66-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.203539"},{"key":"bibr67-17588359231182293","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05219500."},{"key":"bibr68-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"bibr69-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2021.05.007"},{"key":"bibr70-17588359231182293","first-page":"425","volume":"35","author":"Lindegren S","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"bibr71-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.1c00327"},{"key":"bibr72-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262687"},{"key":"bibr73-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.046938"},{"key":"bibr74-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.062604"},{"key":"bibr75-17588359231182293","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.220384"},{"key":"bibr76-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.07.005"},{"key":"bibr77-17588359231182293","first-page":"2967","volume":"10","author":"Leidermark E","year":"2022","journal-title":"J Nucl Med"},{"key":"bibr78-17588359231182293","first-page":"124","volume":"21","author":"Doberenz I","year":"1990","journal-title":"NucCompact"},{"key":"bibr79-17588359231182293","unstructured":"ClinicalTrials.gov. Radioimmunotherapy (\n                      211\n                      At-OKT10-B10) and chemotherapy (Melphalan) before stem cell transplantation for the treatment of multiple myeloma, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04466475"},{"key":"bibr80-17588359231182293","unstructured":"ClinicalTrials.gov. \u00b2\u00b9\u00b9At-OKT10-B10 and fludarabine alone or in combination with cyclophosphamide and low-dose TBI before donor stem cell transplant for the treatment of newly diagnosed, recurrent, or refractory high-risk multiple myeloma, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04579523"},{"key":"bibr81-17588359231182293","unstructured":"ClinicalTrials.gov.\n                      211\n                      At-BC8-B10 followed by donor stem cell transplant in treating patients with relapsed or refractory high-risk acute leukemia or myelodysplastic syndrome, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03670966."},{"key":"bibr82-17588359231182293","unstructured":"ClinicalTrials.gov.\n                      211\n                      At-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03128034"},{"key":"bibr83-17588359231182293","unstructured":"ClinicalTrials.gov. Targeted alpha therapy using astatine (At-211) against differentiated thyroid cancer, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05275946."},{"key":"bibr84-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01612-9"},{"key":"bibr85-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-022-01765-1"},{"key":"bibr86-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06016-z"},{"key":"bibr87-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1080\/17434440.2022.2146999"},{"key":"bibr88-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.03.002"},{"key":"bibr89-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30604-1"},{"key":"bibr90-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.05.003"},{"key":"bibr91-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"bibr92-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"bibr93-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"bibr94-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"bibr95-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4167-0"},{"key":"bibr96-17588359231182293","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010297"},{"key":"bibr97-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.04.008"},{"key":"bibr98-17588359231182293","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3919-6"},{"key":"bibr99-17588359231182293","unstructured":"https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000042995."},{"key":"bibr100-17588359231182293","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.180124"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359231182293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359231182293","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359231182293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:28:46Z","timestamp":1777588126000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359231182293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":100,"alternative-id":["10.1177\/17588359231182293"],"URL":"https:\/\/doi.org\/10.1177\/17588359231182293","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17588359231182293"}}